首页> 外文期刊>Emergency Care Journal >Academy of Emergency Medicine and Care-Society of Clinical Biochemistry and Clinical Molecular Biology consensus recommendations for clinical use of sepsis biomarkers in the emergency department
【24h】

Academy of Emergency Medicine and Care-Society of Clinical Biochemistry and Clinical Molecular Biology consensus recommendations for clinical use of sepsis biomarkers in the emergency department

机译:急诊医学与护理学院-临床生物化学与临床分子生物学学会对急诊室脓毒症生物标志物临床使用的共识性建议

获取原文
       

摘要

Increasing evidence is emerging that the measurement of circulating biomarkers may be clinically useful for diagnosing and monitoring sepsis. Eight members of AcEMC (Academy of Emergency Medicine and Care) and eight members of SIBioC (Italian Society of Clinical Biochemistry and Laboratory Medicine) were identified by the two scientific societies for producing a consensus document aimed to define practical recommendations about the use of biomarkers for diagnosing of sepsis and managing antibiotic therapy in the emergency department (ED). The cumulative opinions allowed defining three grade A recommendations ( i.e. , highly recommended indications), entailing ordering modality (biomarkers always available on prescription), practical use (results should be interpreted according to clinical information) and test ordering defined according to biomarker kinetics. Additional grade B recommendations ( i.e. , potentially valuable indications) entailed general agreement that biomarkers assessment may be of clinical value in the diagnostic approach of ED patients with suspected sepsis, suggestion for combined assessment of procalcitonin (PCT) and Creactive protein (CRP), free availability of the selected biomarker(s) on prescription, adoption of diagnostic threshold prioritizing high negative predictive value, preference for more analytically sensitive techniques, along with potential clinical usefulness of measuring PCT for monitoring antibiotic treatment, with serial testing defined according to biomarker kinetics. PCT and CRP were the two biomarkers that received the largest consensus as sepsis biomarkers (grade B recommendation), and a grade B recommendation was also reached for routine assessment of blood lactate. The assessment of biomarkers other than PCT and CRP was discouraged, with exception of presepsin for which substantial uncertainty in favor or against remained.
机译:越来越多的证据表明,循环生物标志物的测定可能在临床上可用于诊断和监测败血症。两家科学学会确定了八名AcEMC(急诊医学与护理学院)成员和八名SIBioC(意大利临床生物化学与实验室医学协会)来产生共识性文件,以定义有关使用生物标志物的实用建议。在急诊室(ED)诊断败血症并管理抗生素治疗。累积的意见允许定义三个A级推荐(即高度推荐的适应症),需要订购的方式(始终在处方上使用生物标志物),实际使用(应根据临床信息解释结果)和根据生物标志物动力学定义的测试顺序。额外的B级建议(即潜在有价值的适应症)需要达成普遍共识,即生物标志物评估在怀疑患有败血症的ED患者的诊断方法中可能具有临床价值,建议联合评估降钙素(PCT)和活性蛋白(CRP),免费处方中所选生物标志物的可用性,优先考虑高阴性预测值的诊断阈值的采用,对更具分析敏感性的技术的偏爱,以及测量PCT监测抗生素治疗的潜在临床实用性,并根据生物标志物动力学定义了一系列测试。 PCT和CRP是作为败血症生物标志物获得最大共识的两个生物标志物(B级推荐),对于血乳酸的常规评估也达到了B级推荐。不建议对除PCT和CRP以外的生物标志物进行评估,除了普鲁斯皮素外,普利司匹林的优缺点仍然存在很大不确定性。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号